(Q37840260)

24 August 2017

1 reference

title

Acute myeloid leukaemia in the elderly: a review (English)

1 reference

24 August 2017

1 reference

Daniel A Pollyea

1

1 reference

24 August 2017

Holbrook E Kohrt

series ordinal

2

1 reference

24 August 2017

Bruno C Medeiros

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

British Journal of Haematology

24 August 2017

1 reference

24 August 2017

152

1 reference

24 August 2017

5

1 reference

24 August 2017

524-542

1 reference

Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.

24 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Age and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors in Older Patients With Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Priming with granulocyte colony-stimulating factor--relation to high-dose cytarabine in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Treatment of older patients with acute myeloid leukemia--new agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Prevalence of co-morbidity in newly diagnosed patients with cancer: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Pharmacokinetic changes in aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Treatment of acute myeloid leukemia in the elderly: a clinical dilemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Acute myeloid leukemia in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Acute myeloid leukemia and myelodysplastic syndromes in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Older adults: should the paradigm shift from standard therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Enrolling older persons in cancer trials: the effect of sociodemographic, protocol, and recruitment center characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Relation between age and blast cell differentiation in acute myeloid leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Acute myeloid leukemia in the elderly: biological features and search for adequate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

The role of drug efflux pumps in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Abnormally high expression of proteasomes in human leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Current use and future development of gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Current and emerging strategies for the management of acute myeloid leukemia in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

High-dose daunorubicin in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Guidelines on the management of acute myeloid leukaemia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Non-targeted bystander effects induced by ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Acute myeloid leukemia in the elderly: biology and therapeutic strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Antileukemic activity of rapamycin in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Treatment of acute myeloid leukemia in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Treatment of acute myelogenous leukemia with outpatient azacitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

The Ras superfamily at a glance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08470.X

10.1111/J.1365-2141.2010.08470.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference